scispace - formally typeset
M

Michael B. Bracken

Researcher at Yale University

Publications -  298
Citations -  38757

Michael B. Bracken is an academic researcher from Yale University. The author has contributed to research in topics: Pregnancy & Asthma. The author has an hindex of 82, co-authored 297 publications receiving 36614 citations. Previous affiliations of Michael B. Bracken include Yale Cancer Center & Albert Einstein College of Medicine.

Papers
More filters
Journal ArticleDOI

Complement Factor H Polymorphism in Age-Related Macular Degeneration

TL;DR: A genome-wide screen for polymorphisms associated with age-related macular degeneration revealed a polymorphism in linkage disequilibrium with the risk allele representing a tyrosine-histidine change at amino acid 402 in the complement factor H gene.
Journal ArticleDOI

A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study.

TL;DR: In this paper, the authors evaluated the efficacy and safety of methylprednisolone and naloxone in a multicenter randomized, double-blind, placebo-controlled trial in patients with acute spinal-cord injury, 95 percent of whom were treated within 14 hours of injury.
Journal ArticleDOI

International Standards for Neurological and Functional Classification of Spinal Cord Injury

TL;DR: International Standards for Neurological and Functional Classification of Spinal Cord Injury are published and will be used for clinical practice.
Journal Article

The Second National Acute Spinal Cord Injury Study.

TL;DR: The study strongly suggests that methylprednisolone has significant beneficial effects in human spinal cord injury, that these effects occur only when the drug is given within 8 hr, and that it helps even in patients with severe spinal cord injuries.
Journal ArticleDOI

Complement factor H polymorphism in age-related macular degeneration

TL;DR: A genome-wide screen for polymorphisms associated with age-related macular degeneration revealed a polymorphism in linkage disequilibrium with the risk allele representing a tyrosine-histidine change at amino acid 402 in the complement factor H gene.